Gomez, C. (C.)
- Publications
- item.page.relationships.isContributorAdvisorOfPublication
- item.page.relationships.isContributorOfPublication
4 results
Search Results
Now showing 1 - 4 of 4
- Effect of heparin and/or antithrombin III on the generation of endotoxin-induced plasminogen activator inhibitor(Schattauer, 1989) Paramo, J.A. (José Antonio); Rocha, E. (Eduardo); Colucci, M. (M.); Gomez, C. (C.)It has been experimentally shown that endotoxin induces a significant increase in the blood levels of a plasminogen activator inhibitor (PAI). We evaluated the effect of different doses of heparin (5 to 20 IU kg-1 h-1), antithrombin III (10 to 40 U kg-1 h-1 and 240 U/kg as bolus) and of a combination of the two on: 1) the elevation of PAI activity, 2) fibrin deposition in kidneys and 3) mortality in rabbits infused with E. coli lipopolysaccharide. Our results show that heparin plus AT III is able to significantly reduce the generation of endotoxin-induced PAI activity in rabbits' circulation. Low dose of heparin and a bolus injection of AT III both cause a decrease in the generation of PAI at 2 but not at 6 hours of endotoxin infusion. Moreover, fibrin deposits in kidneys of animals receiving heparin plus AT III or a bolus injection of AT III were significantly reduced as compared to control rabbits. The association between low levels of PAI and decreased fibrin deposits is strengthened by the significant correlation (p less than 0.05) found between these two parameters. Finally, the plasma levels of PAI activity at 2 and 6 hours of endotoxin infusion in surviving animals were lower than those observed in animals that died within 2 hours after the end of treatment. We conclude that heparin plus AT III partially prevents the endotoxin-induced generation of PAI activity which seems to correlate with the reduced presence of fibrin deposits in kidneys and with a reduced mortality.
- Evan's syndrome, chronic active hepatitis and focal glomerulonephritis in IgA deficiency(Karger, 1986) Paramo, J.A. (José Antonio); Rocha, E. (Eduardo); Fernandez, J. (Javier); Cuesta, B. (Braulia); Gomez, C. (C.); Pardo, J. (Javier)A 10-year-old female with a complete selective IgA deficiency and recurrent autoimmune disease (chronic active hepatitis, focal glomerulonephritis, hemolytic anemia and thrombopenic purpura) is presented. Both serum IgA and saliva secretory IgA were below the detection limit. The small bowel biopsy using a peroxidase-antiperoxidase technique showed absence of plasma cells secreting IgA. Circulating antibodies against mitochondria, microsomal thyroid antigen were detected as well as rheumatoid factor. Circulating immune complexes were present. A positive Coombs' test and a slightly positive reaction for cryoagglutinins were demonstrated. No alterations in cellular immunity were observed. Clinical and analytical improvement with prednisone and azathioprine was obtained.
- Púrpura trombótica trombocitopénica: tratamiento con plasmaferesis, plasma fresco, antiagregantes plaquetares y corticoides(Universidad de Navarra, 1987) Paramo, J.A. (José Antonio); Hernández, M. (M.); Rocha, E. (Eduardo); Cuesta, B. (Braulia); Gomez, C. (C.); Viteri, C. (César)
- SEOM clinical guidelines for endometrial cancer (2017)(Springer, 2018) Carballo, N. (N.); González-Martín, A. (Adrián); Gutierrez, M. (M.); Gorostidi, M. (M); Redondo, A. M. (Alba M.); Matías-Guiu, X. (Xavier); Gomez, C. (C.); Gil, M. (Miguel); Santaballa, A. (Ana)Endometrial cancer (EC) is the most common gynecological cancer in developed countries. Most patients are diagnosed at an early stage with a low risk of relapse. However, there is a group of patients with a high risk of relapse and poor prognosis. Despite the recent publication of randomized trials, the adjuvant treatment of high-risk EC is still to be defned and there are many open questions about the best approach and the right timing. Unfortunately, the survival of metastatic or recurrent EC is short, due to the poor results of chemotherapy and the lack of a second line of treatment. Advances in the knowledge of the molecular abnormalities in EC have permitted the development of promising targeted therapies.